Education
About Us
Working with TipRanks
Follow Us
Sonnet BioTherapeutics Holdings (SONN)
NASDAQ:SONN
SONN Stock Chart & Stats
$4.75
-$0.13(-7.37%)
At close: 4:00 PM EST
$4.75
-$0.13(-7.37%)
Day’s Range― - ―
52-Week Range$1.08 - $19.30
Previous CloseN/A
Volume154.24K
Average Volume (3M)1.26M
Market Cap
$33.62M
Enterprise Value$4.66M
Total Cash (Recent Filing)$321.30K
Total Debt (Recent Filing)$68.84K
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Aug 18, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding7,077,852
10 Day Avg. Volume396,484
30 Day Avg. Volume1,260,471
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.02
Price to Sales (P/S)235.35
P/FCF Ratio-0.51
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue4.66
Enterprise Value/Gross Profit-4.90
Enterprise Value/Ebitda-0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Sonnet BioTherapeutics Holdings News
SONN FAQ
What was Sonnet BioTherapeutics Holdings’s price range in the past 12 months?
Sonnet BioTherapeutics Holdings lowest stock price was $1.08 and its highest was $19.30 in the past 12 months.
What is Sonnet BioTherapeutics Holdings’s market cap?
Sonnet BioTherapeutics Holdings’s market cap is $33.62M.
When is Sonnet BioTherapeutics Holdings’s upcoming earnings report date?
Sonnet BioTherapeutics Holdings’s upcoming earnings report date is Aug 18, 2025 which is 74 days ago.
How were Sonnet BioTherapeutics Holdings’s earnings last quarter?
Sonnet BioTherapeutics Holdings released its earnings results on May 20, 2025. The company reported -$0.92 earnings per share for the quarter, the consensus estimate of -$0.92 by $0.
Is Sonnet BioTherapeutics Holdings overvalued?
According to Wall Street analysts Sonnet BioTherapeutics Holdings’s price is currently Overvalued.
Does Sonnet BioTherapeutics Holdings pay dividends?
Sonnet BioTherapeutics Holdings does not currently pay dividends.
What is Sonnet BioTherapeutics Holdings’s EPS estimate?
Sonnet BioTherapeutics Holdings’s EPS estimate is -0.49.
How many shares outstanding does Sonnet BioTherapeutics Holdings have?
Sonnet BioTherapeutics Holdings has 7,077,852 shares outstanding.
What happened to Sonnet BioTherapeutics Holdings’s price movement after its last earnings report?
Sonnet BioTherapeutics Holdings reported an EPS of -$0.92 in its last earnings report, expectations of -$0.92. Following the earnings report the stock price went down -5.367%.
Which hedge fund is a major shareholder of Sonnet BioTherapeutics Holdings?
Currently, no hedge funds are holding shares in SONN
Sonnet BioTherapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.6%
Last 30 Days ▲ 10.0%
Last 30 Days ▲ 10.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-40.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-64.54%
Trailing 12-Months
Company Description
Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics Holdings, Inc. is a biotechnology company focused on developing innovative therapies for various diseases using its proprietary synthetic biology platform. The company operates primarily in the biotechnology sector, specializing in the development of biologics that leverage its technology for precision medicine. Sonnet's core products include treatment candidates targeting cancer and other serious conditions, utilizing its unique Sonnet-Engineered Therapeutics (SET) platform to create next-generation therapeutics that aim to enhance efficacy and reduce side effects.
Technical Analysis
Bio Green Med Solution
―
Tenax Therapeutics
―
VYNE Therapeutics
―
Longeveron
―
Calidi Biotherapeutics
―
Ownership Overview
1.59% Insiders
0.39% Mutual Funds
<0.01% Other Institutional Investors
97.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---